Note 4 - Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2019

Notes Tables

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

			Fair Value Measurements at March 31, 2019
			Quoted Prices in		Significant Other		Significant
			Active Markets for		Observable		Unobservable
	Balance at		Identical Assets		Inputs		Inputs
	March 31, 2019		(Level 1)		(Level 2)		(Level 3)
Assets:
Money market funds	$	104,875	$	104,875	$	-	$	-
Total assets	$	104,875	$	104,875	$	-	$	-
Liabilities:
Contingent consideration liability	$	11,900	$	-	$	-	$	11,900
Total liabilities	$	11,900	$	-	$	-	$	11,900

			Fair Value Measurements at December 31, 2018
			Quoted Prices in		Significant Other		Significant
			Active Markets for		Observable		Unobservable
	Balance at		Identical Assets		Inputs		Inputs
	December 31, 2018		(Level 1)		(Level 2)		(Level 3)
Assets:
Money market funds	$	136,052	$	136,052	$	-	$	-
Total assets	$	136,052	$	136,052	$	-	$	-
Liabilities:
Contingent consideration liability	$	11,000	$	-	$	-	$	11,000
Total liabilities	$	11,000	$	-	$	-	$	11,000

Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]

Program	Consideration		Form of Payment at Progenics' Option
AZEDRA	$	8,000	Cash or Progenics common stock
1404		10,000	Cash or Progenics common stock
1095		5,000	Cash or Progenics common stock
	$	23,000

	Consideration		Form of Payment at Progenics' Option
$30 million	$	5,000	Cash or Progenics common stock
$60 million		5,000	Cash or Progenics common stock
$100 million		10,000	Cash or Progenics common stock
$250 million		20,000	Cash or Progenics common stock
$500 million		30,000	Cash or Progenics common stock
	$	70,000

Fair Value Inputs, Assets and Liabilities, Quantitative Information [Table Text Block]

	Fair Value at
	March 31,
	2019		Valuation Technique	Unobservable Input	Assumption
Contingent Consideration Liability:
AZEDRA commercialization	$	7,900	Probability adjusted discounted	Probability of success			100%
			cash flow model	Period of expected milestone achievement			2019
				Discount rate			10%
1095 commercialization		450	Probability adjusted discounted	Probability of success			18%
			cash flow model	Period of expected milestone achievement			2026
				Discount rate			10%
Net sales targets		3,550	Monte-Carlo simulation	Probability of success		18%	-	90%
				Discount rate			10%
Total	$	11,900

	Fair Value at
	December 31,
	2018		Valuation Technique	Unobservable Input	Assumption
Contingent Consideration Liability:
AZEDRA commercialization	$	7,050	Probability adjusted discounted	Probability of success			90%
			cash flow model	Period of expected milestone achievement			2019
				Discount rate			10%
1095 commercialization		450	Probability adjusted discounted	Probability of success			18%
			cash flow model	Period of expected milestone achievement			2026
				Discount rate			10%
Net sales targets		3,500	Monte-Carlo simulation	Probability of success		18%	-	90%
				Discount rate			10%
Total	$	11,000

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Liability - Contingent Consideration
	Fair Value Measurements Using
	Significant Unobservable Inputs
	(Level 3)
	Three Months Ended March 31,
	2019		2018
Balance at beginning of period	$	11,000	$	16,800
Fair value change included in net loss		900		800
Balance at end of period	$	11,900	$	17,600
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$	900	$	800